Tag: bronchiolitis
-
Bronchiolitis Update: Beyfortus Indication Expanded to 24 Months for Vulnerable Kids
What Beyfortus is and how it works Beyfortus, also known as nirsevimab, is a monoclonal antibody designed to protect young children from severe bronchiolitis caused by respiratory syncytial virus (RSV). Unlike vaccines, Beyfortus provides passive immunity through a single intramuscular injection that covers the upcoming RSV season, reducing the risk of hospitalization for RSV-related illness…
-
Bronchiolitis and Beyfortus: Expanded indication for vulnerable children up to 24 months
Overview: Beyfortus and the fight against RSV bronchiolitis Bronchiolitis is a common respiratory illness in young children, most notably caused by the respiratory syncytial virus (RSV). Protecting vulnerable infants and toddlers from severe RSV infections has long been a priority for pediatric care teams. Beyfortus, the synthetic antibody nirsevimab developed by AstraZeneca and marketed by…